There are currently 1248 clinical trials in Seattle, Washington looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Washington, Seattle Children's Hospital, Fred Hutchinson Cancer Research Center and University of Washington Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
US National OCS Heart Perfusion (OHP) Registry
Recruiting
This Registry is a sponsor initiated, multi-center, observational post-approval registry with independent academic oversight.
Gender:
ALL
Ages:
All
Trial Updated:
12/05/2024
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Heart Transplant
The TELENEO Trial: a Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
Recruiting
The purpose of this study is to evaluate the impact of real-time audio-video telemedicine consults with a neonatologist (termed teleneonatology) on the early health outcomes of at-risk neonates delivered in community hospitals.
Gender:
ALL
Ages:
0 days and above
Trial Updated:
12/05/2024
Locations: Seattle Children's Hospital, Seattle, Washington +1 locations
Conditions: Death; Neonatal, Morbidity;Newborn
Study of Safety and Efficacy of RGT-61159 in Adults with Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Recruiting
Phase 1 study to evaluate safety, tolerability and anti-tumor activity of RGT-61159 in patients with ACC or CRC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/05/2024
Locations: Fred Hutchinson Cancer Center, Seattle, Washington
Conditions: Adenoid Cystic Carcinoma, Colorectal Cancer
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Recruiting
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is pre... Read More
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
12/04/2024
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Hematologic Malignancy, AML, ALL, BPDCN, MDS, Lymphoblastic Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Hodgkin Lymphoma, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia
Effect of High-Intensity Exercise to Attenuate Cognitive Function Limitations and Train Exercise Habits in Older People Living With HIV
Recruiting
People aging with HIV are at higher risk for Alzheimer's disease and related dementias, and although physical activity is a promising target to mitigate such risk, this population engages in low levels of physical activity. Few studies have tested cognitive effects of exercise interventions or examined mechanisms of adherence to long-term exercise among diverse samples of midlife and older people with HIV. The current study will leverage an existing R01 to address these gaps and provide implicat... Read More
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
12/04/2024
Locations: University of Washington, Seattle, Washington
Conditions: HIV Infections, Cognitive Impairment
Optimizing Infection Prophylaxis Prior to Shoulder Surgery
Recruiting
The goal of this interventional study is to determine the amount of skin C. acnes reduction with increased pressure during the chlorhexidine gluconate, brand name ChloraPrep, application. The main question it aims to answer is: Does changing the pressure applied during the ChloraPrep application impact the amount of C. acnes bacteria on the skin after one hour? Researchers will compare ChloraPrep applied at a pressure similar to a gentle wipe to ChloraPrep applied at a pressure similar to a mas... Read More
Gender:
MALE
Ages:
Between 18 years and 89 years
Trial Updated:
12/04/2024
Locations: University of Washington, Seattle, Washington
Conditions: Arthroplasty Shoulder, Periprosthetic Joint Infection
Physician Modified Endovascular Grafts
Recruiting
The primary objectives of this study are to determine whether physician modified endovascular grafts (PMEG) and specified company manufactured devices (all to be referred throughout jointly as the investigational devices) are a safe and effective method of treating patients with elective, symptomatic or ruptured juxtarenal aortic aneurysms in those patients considered to be unsuitable candidates for open surgical repair and have limited or no other options for treatment. Secondary objectives inc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: Harborview Medical Center, Seattle, Washington
Conditions: Abdominal Aortic Aneurysms
Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants
Recruiting
In this phase II trial, the investigators overarching goal is to demonstrate the feasibility and potential benefit of darbepoetin (Darbe) plus slow-release intravenous (IV) iron to decrease transfusions, maintain iron sufficiency and improve the neurodevelopmental outcomes of preterm infants. Investigators hypothesize that in infants \< 32 completed weeks of gestation, combined treatment with Darbe plus Ferumoxytol (FMX) or Darbe plus low molecular weight iron dextran (LMW-ID) will: 1) be safe,... Read More
Gender:
ALL
Ages:
3 days and below
Trial Updated:
12/03/2024
Locations: University of Washington, Seattle, Washington
Conditions: Prematurity, Iron-deficiency, Iron Deficiency Anemia, Iron Malabsorption
Disulfiram for Treatment of Retinal Degeneration
Recruiting
Aberrant retinoic acid signaling driven by the degenerating outer retina leads to pathological changes to the inner retina. The resulting hyperactivity of retinal ganglion cells leads to further diminution of the remaining vision in those afflicted with inherited retinal diseases. Inhibition of this pathway has led to improved visual function in murine models of retinal degeneration. This can be accomplished in humans with the FDA-approved irreversible inhibitor of aldehyde dehydrogenases, disul... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Washington-South Lake Union Retina Center, Seattle, Washington
Conditions: Inherited Retinal Dystrophy Primarily Involving Sensory Retina
BASIS-T Efficacy Trial
Recruiting
For the approximately one in five children with social, emotional, and behavioral (SEB) challenges, accessible evidence-based prevention practices (EBPPs) are critical. In the United States, schools are the primary service setting for children's SEB service delivery but EBPPs are rarely adopted or implemented by educators (e.g., teachers) with sufficient fidelity to see effects. Given that individual behavior change is ultimately required for successful implementation, focusing on individual-lev... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Washington, Seattle, Washington
Conditions: Behavior, Child
Lung Transplant READY CF 2: CARING CF Ancillary RCT
Recruiting
Lung transplant is an option for treating end-stage lung disease in cystic fibrosis (CF). In the United States, more people with CF and low lung function die each year than undergo lung transplant. More than half of people with CF who die without a lung transplant were never referred for consideration. Patient preference not to undergo lung transplant may account for 25-40% of decisions to defer referral. Patients' health discussion networks function to support individuals in health related mat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2024
Locations: University of Washington Medical Center - Montlake, Seattle, Washington
Conditions: Cystic Fibrosis
A Study to Evaluate the Safety of AB-1003 (Previously LION-101) in Subjects With Genetic Confirmation of LGMD2I/R9 (Part1)
Recruiting
The purpose of this study is to evaluate the safety and tolerability of a single intravenous infusion of AB-1003 in adults diagnosed with limb girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). Participants will be treated in sequential, dose-level cohorts. (Part 1)
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
11/26/2024
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: Limb Girdle Muscular Dystrophy, Limb-Girdle Muscular Dystrophy Type 2, LGMD2I, Muscular Dystrophy, LGMD2, LGMD, FKRP, FKRP Mutation, Fukutin Related Protein